Advertisement


Daniel E. Spratt, MD, on Prostate Cancer: Relugolix vs Leuprolide

2020 ASTRO Annual Meeting

Advertisement

Daniel E. Spratt, MD, of the University of Michigan Rogel Cancer Center, discusses phase III results of the HERO trial, which suggested benefits of the oral medication relugolix: a substantially faster time to castration with longer duration, fewer cardiac events, and a faster return to normal testosterone levels compared with leuroplide (Abstract 35).



Related Videos

Breast Cancer

Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Deintensifying Radiation Therapy

Youssef Zeidan, MD, PhD, of the American University of Beirut Medical Center, discusses study findings showing that breast-conserving surgery, whole-breast irradiation, and t...

Prostate Cancer

Justin Oh, MD, on Prostate Cancer: Brachytherapy vs External-Beam Radiation Therapy

Justin Oh, MD, of the University of British Columbia, discusses results from the ASCENDE-RT trial, which compared a low-dose–rate brachytherapy boost to a dose-escalated exte...

Prostate Cancer

Linda G.W. Kerkmeijer, MD, PhD, on Prostate Cancer: Adding a Focal Boost to External-Beam Radiotherapy

Linda G.W. Kerkmeijer, MD, PhD, of the University Medical Center Utrecht and Radboud University Medical Center, discusses results from the phase III FLAME trial, which explor...

Breast Cancer

Juliane Hörner-Rieber, MD, on Breast Cancer: Boosting Intensity-Modulated and Conventional Radiotherapies

Juliane Hörner-Rieber, MD, of Heidelberg University Hospital, discusses phase III results of the MINT trial, which showed that conventionally fractionated intensity-modulated...

Prostate Cancer

Daniel E. Spratt, MD, on Prostate Cancer: Short-Term Adjuvant vs Neoadjuvant Hormone Therapy

Daniel E. Spratt, MD, of the University of Michigan Rogel Cancer Center, discusses a pooled analysis of two phase III trials showing adjuvant androgen-deprivation therapy (AD...

Advertisement

Advertisement



Advertisement